Rockwell Medical, Inc. (NASDAQ:RMTI) is reporting second quarter earnings results on Monday 10th August 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.14 per share.
For the full year, analysts predict revenues of $ 68.11 million, while looking forward to loss of $ 0.51 per share.
Previous Quarter Performance
Rockwell Medical, Inc. announced loss for the first quarter of $ 0.12 per share, from the revenue of $ 15.86 million. The quarterly earnings declined 42.11 percent while revenues compared with the same quarter last year.
Wall street analysts are predicting, RMTI to report 1Q20 loss of $ 0.12 per share from revenue of $ 15.80 million. The bottom line results street analysts by $ 0 or , at the same time, top line results outshined analysts by $ 0.06 million or 0.38 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Rockwell Medical, Inc.
Stock Performance
According to the previous trading day, closing price of RMTI was $ 1.67, representing a 27.48 % increase from the 52 week low of $ 1.31 and a 56.62 % decrease over the 52 week high of $ 3.85.
The company has a market capital of $ 115.35 million and is part of the Healthcare sector and Drug Manufacturers – Major industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”RMTI” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Rockwell Medical, Inc. will be hosting a conference call at 4:30 PM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.rockwellmed.com
Rockwell Medical, Inc. operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis.
